Pricing and reimbursement of orphan drugs in Italy

被引：0

作者：

Lopatriello, S.

Schivazappa, C.

Negrini, C.

Berto, P.

机构：

[1] PBE Consulting, Verona, Italy

[2] PBE Consulting, Milan, Italy

来源：

VALUE IN HEALTH | 2006年 / 9卷 / 06期

关键词：

D O I：

10.1016/S1098-3015(10)63221-4

中图分类号：

F [经济];

学科分类号：

02 ;

摘要：

引用

页码：A208 / A209

页数：2

共 50 条

[41] ASSESSMENT OF THE ORPHAN DRUG PRICING AND REIMBURSEMENT LANDSCAPE IN THE ASIA PACIFIC REGION
Mukku, S. R.
Pang, F.
VALUE IN HEALTH, 2010, 13 (07) : A537 - A537
[42] MULTIPLE INDICATION PRICING, REIMBURSEMENT AND FUNDING DYNAMICS: THE CASE OF ORPHAN INDICATIONS
Wild, L.
Forster, L.
VALUE IN HEALTH, 2011, 14 (07) : A335 - A336
[43] Potential impact of the implementation of multiple-criteria decision analysis (MCDA) on the Polish pricing and reimbursement process of orphan drugs
Kolasa, Katarzyna
Zwolinski, Krzysztof M.
Kalo, Zoltan
Hermanowski, Tomasz
ORPHANET JOURNAL OF RARE DISEASES, 2016, 11
[44] ANALYSIS OF FUNDING CONDITIONS FOR ORPHAN MEDICINES IN SPAIN: TRENDS IN PRICING & REIMBURSEMENT
Orchard, M.
VALUE IN HEALTH, 2024, 27 (12) : S362 - S363
[45] A REVIEW AND EVALUATION OF REIMBURSEMENT OUTCOMES FOR NON-ORPHAN AND ORPHAN DRUGS IN IRELAND IN 2023
Greenwood, M.
Lyttle, S. J.
Roberts, G.
Zarifi, O.
Mumford, A.
VALUE IN HEALTH, 2024, 27 (12) : S353 - S353
[46] IS THERE NO OPTIMAL APPROACH FOR ORPHAN DRUGS TO PATIENT ACCESS? RARE DISEASE IS NOT RARE AND NEEDS TO DEVELOP THE NEW PRICING AND REIMBURSEMENT SOLUTION
Kim, S.
Cho, Y.
Shim, S.
Lee, J.
Kim, W.
Bae, K.
VALUE IN HEALTH, 2011, 14 (07) : A354 - A355
[47] The national drug formulary listing process for orphan drugs in South Korea: narrative review focused on pricing and reimbursement pathways
Bang, Joon Seok
Lee, Jong Hyuk
EXPERT OPINION ON ORPHAN DRUGS, 2021, 9 (04): : 105 - 112
[48] Potential impact of the implementation of multiple-criteria decision analysis (MCDA) on the Polish pricing and reimbursement process of orphan drugs
Katarzyna Kolasa
Krzysztof M. Zwolinski
Zoltan Kalo
Tomasz Hermanowski
Orphanet Journal of Rare Diseases, 11
[49] REIMBURSEMENT OF ORPHAN DRUGS UNDER EARLY BENEFIT ASSESMENT IN GERMANY
Ecker, T.
Schneider, D.
Bot, D.
VALUE IN HEALTH, 2016, 19 (03) : A281 - A281
[50] ACCESSIBILITY OF ORPHAN DRUGS IN KOREA: REIMBURSEMENT AND SUPPLY REFUSAL EXAMPLE
Yun, J.
Bae, S.
VALUE IN HEALTH, 2018, 21 : S44 - S44

← 1 2 3 4 5 →